Renalytix
plc
("Renalytix" or the
"Company")
Cancellation of Ordinary
Shares
Total Voting
Rights
LONDON and NEW YORK, 6 November 2024
- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an
artificial intelligence-enabled in vitro diagnostics company,
focused on optimizing clinical management of kidney disease to
drive improved patient outcomes and advance value-based care,
announces that, following the Placing and Subscription undertaken
by the Company which was announced on 30 September 2024
(the "Fundraising
Announcement"), one of the subscribers is limiting
his Subscription in the Fundraise to £281,955, which is 2,422,723
shares or £218,045 short of his allocated amount. In addition,
8,877 shares have not been settled with an accounts payable and
debt holder which equates to £798.93.
Cancellation of Ordinary Shares and Total Voting
Rights
The Company will therefore cancel
2,431,600 Ordinary Shares at or around 8.00 am tomorrow, 7 November
2024 (the "Cancellation").
Following the Cancellation, the
issued share capital of the Company will consist
of 331,206,012 Ordinary Shares. Each Ordinary
Share carries one vote and there are no shares held in
treasury. Therefore, the total number of voting rights in the
Company following Cancellation tomorrow will be 331,206,012 and
this figure may be used by shareholders as the denominator for the
calculations by which they can determine if they are required to
notify their interest in, or a change of their interest in the
Company under the Financial Conduct Authority's Disclosure and
Transparency Rules.
Capitalised terms used in this
announcement have the meanings given to them in the Fundraising
Announcement, unless the context provides otherwise.
The person responsible for making
this Announcement on behalf of the Company is James McCullough,
Chief Executive Officer.
For further information, please
contact:
|
Renalytix Plc
James McCullough, CEO
|
www.renalytix.com
Via Walbrook
PR
|
|
Stifel Nicolaus Europe Limited (Nominated Adviser and Joint
Broker)
Nicholas Moore / Nick Harland / Ben
Good
|
Tel: 020 7710
7600
|
|
Oberon Capital (Joint Broker and Sole
Bookrunner)
Mike Seabrook / Nick Lovering /
Jessica Cave
|
Tel: 020 3179
5300
|
|
Walbrook PR Limited
Alice Woodings
|
Tel: 020 7933
8780 or renalytix@walbrookpr.com
Mob: 07407
804 654
|
|
CapComm Partners
Peter DeNardo
|
Tel:
415-389-6400 or investors@renalytix.com
|
|
|
| |
About Renalytix plc
Renalytix (LSE: RENX) (OTCQB: RNLXY)
is an artificial intelligence enabled in-vitro diagnostics and
laboratory services company that is the global founder and leader
in the field of bioprognosis™ for kidney health. In late 2023, our
kidneyintelX.dkd test was recognized as the first and only
FDA-authorized prognostic test to enable early-stage CKD (stages
1-3b) risk assessment for progressive decline in kidney function in
T2D patients. By understanding how disease will progress, patients
and clinicians can take action earlier to improve outcomes and
reduce overall health system costs. For more information,
visit www.renalytix.com.
